A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

Inclusion Criteria

• •A high resolution CT scan performed in the 6 months prior to screening associated with one of the following conditions and confirmed using guidelines, as per American Thoracic Society (ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association (ALAT):
• •* Major IIPs (idiopathic interstitial pneumonias) diagnosis or suspected as one of the following:
• •* Idiopathic pulmonary fibrosis
• •* Idiopathic nonspecific interstitial pneumonia
• •* Respiratory bronchiolitis-interstitial lung disease
• •* Desquamative interstitial pneumonia
• •* Cryptogenic organizing pneumonia
• •* Acute interstitial pneumonia
• •* Rare IIPs diagnosis by one of the following:
• •* Idiopathic lymphoid interstitial pneumonia
• •* Idiopathic pleuroparenchymal fibroelastosis
• •* Unclassifiable idiopathic interstitial pneumonias
• •* Chronic hypersensitivity pneumonitis
• •* Occupational lung disease
• •* Connective Tissue Disease associated with IPF (CTD-ILD)
• •* Interstitial Pneumonia with Autoimmune Features (IPAF)
• •Have been using oxygen therapy by nasal cannula for at least 4 weeks (including use limited to exertion)
• •6MWD ≥ 100 meters and ≤ 400 meters at screening and Baseline/Randomization visits.
• •World Health Organization (WHO) Functional Class II-IV
• •Forced Vital Capacity ≥ 40% predicted within the 60 day Screening period
• •Age between 18 and 80 years (inclusive) at screening